WallStSmart
IKT

Inhibikase Therapeutics Inc

NASDAQ: IKT · HEALTHCARE · BIOTECHNOLOGY

$1.93
-0.52% today

Updated 2026-05-05

Market cap
$254.82M
P/E ratio
P/S ratio
10.39x
EPS (TTM)
$-0.49
Dividend yield
52W range
$1 – $2
Volume
1.4M

Inhibikase Therapeutics Inc (IKT) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item2016201720182019202020212022202320242025
Revenue$967386.00$2.06M$4.04M$1.12M$698468.00$3.10M$123440.00$260500.00$0.00$0.00
Revenue growth (YoY)+113.0%+96.1%-72.2%-37.8%+343.9%-96.0%+111.0%-100.0%
Cost of revenue$846386.00$1.76M$3.65M$2.55M$893802.00$11.36M$6723.00$13.62M$26272.00$60499.00
Gross profit$121000.00$305245.00$4.04M$-1.43M$698468.00$3.10M$116717.00$-13.36M$-26272.00$-60499.00
Gross margin12.5%14.8%100.0%-127.4%100.0%100.0%94.6%-5127.8%
R&D$846386.00$1.76M$3.65M$2.55M$893802.00$11.36M$12.03M$13.62M$17.21M$29.79M
SG&A$2.52M$4.27M$2.62M$6.51M$6.22M$6.68M$11.38M$23.56M
Operating income$-613288.00$-405130.00$-2.12M$-5.70M$-2.82M$-14.77M$-18.13M$-20.09M$-28.59M$-45.95M
Operating margin-63.4%-19.7%-52.5%-507.5%-403.5%-476.2%-14686.2%-7712.0%
EBITDA$-2.12M$-5.70M$-2.82M$-14.77M$-18.05M$-19.91M$-27.49M$-45.89M
EBITDA margin0.0%0.0%-52.5%-507.5%-403.5%-476.2%-14620.4%-7643.9%
EBIT$-613288.00$-405130.00$-2.12M$-5.70M$-2.82M$-14.77M$-18.05M$-20.09M$-27.52M$-45.95M
Interest expense$0.00$0.00$30332.00$24835.00$29402.00$19923.00$74453.00$74453.00
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-628737.00$-436075.00$-2.15M$-5.75M$-2.88M$-14.81M$-18.05M$-19.03M$-27.52M$-48.26M
Net income growth (YoY)+30.6%-393.6%-167.0%+49.9%-414.6%-21.9%-5.4%-44.6%-75.4%
Profit margin-65.0%-21.2%-53.3%-511.9%-411.9%-477.5%-14625.9%-7304.8%